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Abstract
Background: Matrix metalloproteinase-3 (MMP3) is implicated in the pathogenesis and progression of atherosclerotic
lesions. Previous studies suggested that MMP3 expression is influenced by a polymorphism (known as the 5A/6A
polymorphism) in the promoter of the MMP3 gene and that this polymorphism is located within a cis-element that interacts
with the transcription factor NFkB. In the present study, we sought to investigate whether MMP3 and NFkB were co-
localized in atherosclerotic lesions and whether NFkB had differential effects on the two alleles of the MMP3 5A/6A
polymorphism.
Methodology/Principal Findings: Immunohistochemical examination showed that MMP3 and both the NFkB p50 and p65
subunits were expressed abundantly in macrophages in atherosclerotic lesions and that MMP3 expression was co-localized
with p50 and p65. Chromatin immunoprecipitation experiments showed interaction of p50 and p65 with the MMP3
promoter in macrophages, with greater binding to the 5A allele than to the 6A allele. Reporter gene assays in transiently
transfected macrophages showed that the 5A allele had greater transcriptional activity than the 6A allele, and that this
allele-specific effect was augmented when the cells were treated with the NFkB activator lipopolysaccharides or co-
transfected with p50 and/or p65 expressing plasmids, but was reduced when the cells were treated with the NFkB inhibitor
6-Amino-4-(4-phenoxyphenylethylamino)-quinazoline or transfected with a dominant negative mutant of IkB kinase-b.
Conclusion: These results corroborate an effect of the 5A/6A polymorphism on MMP3 transcription and indicate that NFkB
has differential effects on the 5A and 6A alleles.
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Introduction
Atherosclerotic plaque rupture is the most common cause of acute
clinical ischemic events associated with coronary artery disease [1]. A
typical atherosclerotic plaque contains a lipid core covered by a
fibrous cap, and plaque rupture is mostly the result of fibrous cap
fissuring [1,2]. There is evidence indicating that increased expression
of matrix metalloproteinase-3 (MMP3) in the atherosclerotic plaque
promotes plaque rupture [3–5]. MMP3 is abundantly expressed by
macrophages in atherosclerotic plaques, particularly in the lateral
regions of the fibrous cap where fissuring is most likely to occur [3,4].
This protease is capable of degrading several major structural matrix
proteins present in atherosclerotic plaques [6,7]. A study of a mouse
model of atherosclerosis has shown that knocking out MMP3 results
in increased amounts of matrix proteins in atherosclerotic lesions, a
feature of more stable plaques [5].
The transcription of the MMP3 gene is tightly regulated [8]. We
and others have shown that its transcription is influenced by a
polymorphism in the promoter of the gene [9,10]. The
polymorphism (dbSNP ID rs3025058), known as the 5A/6A
polymorphism, is due to a single base deletion (or insertion) in a
run of thymidines, resulting in one allele (the 5A allele) having 5
thymidines and the other allele (the 6A allele) having 6 thymidines,
at nucleotide positions from 21608 to 21612 (or 21613) relative
to the transcription start site. Previously studies by our and other
groups have demonstrated that the 5A allele has greater promoter
activity than the 6A allele [9,10]. In agreement, it has also been
shown that MMP3 mRNA and protein levels in arterial tissues are
higher in individuals who are homozygous for the 5A allele than in
those who are homozygous for the 6A allele, with intermediate
levels in heterozygous individuals [11]. Genetic epidemiological
studies have shown an association between the 5A allele and
increased risk of myocardial infarction and several other
cardiovascular disorders [12–15].
MMP3 transcription is modulated by the transcription factor
NFkB [16–19] and there is evidence indicating that the DNA
sequence encompassing the 5A/6A polymorphic site can interact
with NFkB [20]. In the present study, we sought to investigate
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whether MMP3 and NFkB were co-expressed in atherosclerotic
lesions and to characterize the regulatory effect of NFkB on the
MMP3 gene 5A and 6A alleles.
Results
We carried out an immunohistochemical analysis to determine
whether MMP3 and NFkB were co-expressed in atherosclerotic
lesions. The analysis showed that MMP3 and both the NFkB p50
and p65 subunits were expressed abundantly in macrophages in
atherosclerotic lesions and were also present in smooth muscle cells
in these tissues (Figure 1). Importantly, we found that MMP3
expression was co-localized with p50 and p65 in these lesions,
although this was not seen in every cell (Figure 2).
We then performed chromatin immunoprecipitation experi-
ments in THP1 monocytes to study whether NFkB could interact
with the MMP3 gene promoter. The experiments showed binding
of p50 and p65 to the MMP3 promoter in these cells (Figure 3).
We then investigated whether the MMP3 5A/6A polymorphism
had an effect on NFkB binding. Using the THP1 cell line (these
cells are heterozygous for the MMP3 5A/6A polymorphism), we
compared the relative amounts of chromatins of the 5A and 6A
alleles respectively, precipitated using anti-NFkB antibodies. We
found that both an anti-p50 antibody and an anti-p65 antibody
precipitated greater amount of 5A allele chromatin than 6A allele
chromatin (Figure 4), suggesting that NFkB interacted more
readily with the 5A allele than the 6A allele.
To further characterize the effect of NFkB on MMP3 5A and
6A alleles, we performed transfection and luciferase reporter assays
in which macrophages were transfected with plasmids containing a
MMP3 gene promoter sequence corresponding to either the 5A or
6A allele and a firefly luciferase reporter gene, and treated the
transfected cells with lipopolysaccharide (LPS), an endotoxin
stimulus of NFkB activation. These experiments demonstrated
that without LPS stimulation, luciferase activity in cells transfected
with the 5A allele construct was 2.4 fold greater than that in cells
transfected with the 6A allele construct (p,0.01), confirming that
the 5A allele has higher promoter activity than the 6A allele
(Figure 5). More importantly, the experiments showed that in cells
transfected with the 5A allele construct, luciferase activity was
increased by LPS treatment, whereas in cells transfected with the
6A allele construct, LPS treatment did not increase luciferase
activity (Figure 5), which is consistent with the notion that NFkB
acts more effectively on the 5A allele than the 6A allele.
To verify that NFkB has differential effects on the 5A and 6A
alleles, we co-transfected macrophages (RAW264 cells) with the
5A or 6A construct together with p50 and/or p65 expressing
plasmids. The experiment showed that over-expressing p50 or p65
resulted in an increase in luciferase activity in cells transfected with
the 5A construct and this upregulatory effect was further increased
when both the p50 and p65 subunits were overexpressed (Figure 6).
In contrast, in cells transfected with the 6A construct, there was
only a small increase in luciferase activity only when both the p50
and p65 subunits were overexpressed (Figure 6).
To further verify the effect of NFkB, we examined whether the
NFkB inhibitor 6-Amino-4-(4-phenoxyphenylethylamino)-quina-
zoline had an effect on luciferase activity in cells transfected with
the 5A or 6A construct. The experiment showed that the NFkB
inhibitor reduced luciferase activity, most notably in cells
transfected with the 5A allele construct (Figure 7).
Figure 1. Macrophages and smooth muscle cells in atherosclerotic plaques express MMP3 and NFkB. Sections (4 mm) of paraffin
embedded tissue blocks of atherosclerotic plaques were subjected to double immunostaining of MMP3 and the macrophage marker CD68 (A and B),
MMP3 and the smooth muscle cell marker SMA (C and D), p50 and CD68 (E and F), p50 and SMA (G and H), p65 and CD68 (I and J), p65 and SMA (K
and M), using rabbit polyclonal NFkB p50 and MMP3 antibodies (Abcam), a rabbit monoclonal NFkB p65 antibody (Abcam), and mouse monoclonal
CD68 and smooth muscle actin (SMA) antibodies (DAKO), respectively, and goat anti-rabbit or anti-mouse secondary antibodies (Thermo/LabVision).
The double immunostaining was visualized with Liquid Permanent Red chromogen (Dako) and Vector Blue chromogen (Vector Labs). Pink colour
indicates expression of MMP3 (A, B, C and D), p50 (E, F, G and H) or p65 (I, J, K and M). Blue colour indicates expression of CD68 (A, B, E, F, I and J) or
SMA (C, D, G, H, K and M). Arrow indicates cell co-expressing MMP3 with CD68 (B) or SMA (D), p50 with CD68 (F) or SMA (H), and p65 with CD68 (J) or
SMA (M). 200X magnification in A, C, E, G, I and K; 400X magnification in B, D, F, H, J and M.
doi:10.1371/journal.pone.0009902.g001
Allelic Regulation of MMP3
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9902
Since NFkB is activated through the action of IkB kinases
(IKK), we investigated whether suppression of IKK activity would
have differential effects on the 5A and 6A alleles. The experiment
showed that expression of a dominant negative mutant of IKKb
resulted in a significant reduction in luciferase activity, especially
in cells transfected with the 5A allele construct which showed a
60% reduction (p,0.01, Figure 8).
Discussion
Our study demonstrates that MMP3 and NFkB are colocalized
in macrophages and smooth muscle cells in atherosclerotic
plaques. With the use of the chromatin immunoprecipitation
technique, we showed that NFkB can interact with the MMP3
gene promoter and that this transcription factor binds more
readily to the 5A allele than the 6A allele. In line with this finding,
reporter assays in transiently transfected macrophages showed that
the 5A allele has greater transcriptional activity than the 6A allele,
and that this allele-specific effect was augmented in cells treated
with the NFkB activator LPS or co-transfected with p50 and/or
p65 expressing plasmids, but was reduced when the cells were
treated with the NFkB inhibitor 6-Amino-4-(4-phenoxypheny-
lethylamino)-quinazoline or transfected with a dominant negative
mutant of IkB kinase-b. Taken together, these results indicate that
the 5A/6A polymorphism influences MMP3 transcription due to
differential effects of NFkB on the 5A and 6A alleles.
MMP3 has proteolytic activity on types III, IV and V collagen,
proteoglycans, laminin, fibronectin and elastin [6,7], which are the
principal components of the extracellular matrix of the arterial
wall and provide the strength of the atherosclerotic plaque to
withstand the mechanical stress imposed on it by the blood
Figure 2. MMP3 and NFkB are co-localized in atherosclerotic plaques. Sections (4 mm) of paraffin embedded tissue blocks of atherosclerotic
plaques were subjected to double immunostaining of MMP3 and p50 (A, B, and C) or MMP3 and p65 (D, E and F), using rabbit polyclonal NFkB p50
and MMP3 antibodies (Abcam) and a rabbit monoclonal NFkB p65 antibody (Abcam), respectively, and goat anti-rabbit secondary antibodies
(Thermo/LabVision). The double immunostaining was visualized with Liquid Permanent Red chromogen (Dako) and Vector Blue chromogen (Vector
Labs). Pink colour indicates expression of p50 (A, B and C) or p65 (D, E and F). Blue colour indicates expression of MMP3 (A, B, C, D, E and F. Arrow
indicates cell co-expressing MMP3 with p50 (B and C) or with p65 (E and F). 2006magnification in A and D; 4006magnification in B, C, E and F.
doi:10.1371/journal.pone.0009902.g002
Figure 3. Interaction of p50 and p65 with MMP3 gene
promoter. Chromatin proteins and DNA in THP1 cells were cross-
linked in 1% formaldehyde for 10 minutes. Cells were then lysed, and
the lysate sonicated to reduce DNA length to 200–1000 bp. The
sonicated chromatin was subjected to immunoprecipitation using a
p50 or p65 antibody, with rabbit IgG as a control, followed by PCR
amplification of 406 bp and 407 bp DNA fragments surrounding the
MMP3 gene 5A/6A site and then agarose gel electrophoresis of the PCR
products. Intensity of bands on the agarose gels were quantified with
the computer software ImageJ. The fold enrichment of DNA
precipitated with p50 antibody or p65 antibody, relative to the IgG
control, was calculated by comparing the intensity of the band of the
amplicon from the p50 or p65 antibody precipitate to the intensity of
the band of the amplicon from the IgG control. The graph shows fold
enrichments of DNA precipitated with p50 antibody or p65 antibody,
relative to the IgG control. Data shown are mean (6 standard error of
mean) from four independent experiments. * denotes p,0.05
comparing DNA precipitated with p50 antibody or p65 antibody to
the IgG control.
doi:10.1371/journal.pone.0009902.g003
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circulation [21]. In addition, MMP3 is an activator of several other
MMPs including MMP-1, -7, -8, -9 and -13 [22–24] which are
also important players in atherogenesis and plaque rupture [4,25–
28]. There is evidence indicating that increased MMP3 expression
in atherosclerotic plaque renders the plaque prone to rupture [3–
5]. Plaque rupture is the most common cause of acute clinical
ischemic events such as myocardial infarction and stroke [1].
Thus, an insight into the molecular mechanisms that govern the
regulation of MMP3 expression will enhance our understanding of
the pathogenesis of atherosclerosis and plaque rupture.
It is now widely accepted that atherosclerosis is a chronic
inflammatory disease of the vessel wall [29]. NFkB is a key
regulator of inflammation and can mediate the induction of more
than 160 genes, many of which have a documented role in
atherosclerosis [30]. Previous studies have shown that NFkB plays
an important role in the regulation of MMP3 expression [16–19].
However, the element(s) in the MMP3 gene that mediate(s) the
regulatory effect of NFkB had not yet been identified. Our present
study indicates that the sequence encompassing the 5A/6A site is
likely to be an NFkB responsive site.
The 5A/6A polymorphism has been associated with risk of
myocardial infarction [12,13,31]. In addition, it has been
associated with several other cardiovascular diseases including
cardiac mortality in patients with heart failure [32], coronary
aneurysm [33], restenosis after coronary angioplasty [34,35],
carotid atherosclerosis and stroke [36–38]. Studies have shown
that MMP3 mRNA and protein levels in ex vivo tissues including
arteries are highest in 5A homozygotes, intermediate in hetero-
zygotes and lowest in 6A homozygotes [11,39], and that the 5A
allele has greater promoter activity and MMP3 transcription than
the 6A allele [9,10], although the molecular mechanism
underlying the effect of this polymorphism on MMP3 gene
promoter activity and transcription is unclear. The results of the
present study corroborate the regulatory effect of the 5A/6A
Figure 4. The MMP3 gene 5A allele more readily interacts with p50 and p65, than the 6A allele. Chromatin proteins and DNA in THP1
cells were cross-linked in1% formaldehyde for 10 minutes. Cells were then lysed, and the lysate sonicated to reduce DNA length to 200–1000 bp. The
sonicated chromatin was subjected to immunoprecipitation using a p50 or p65 antibody, or incubated with a rabbit IgG, followed by PCR
amplification of 179 bp and 180 bp DNA fragments surrounding the MMP3 gene 5A/6A site using fluorescence labelled primers. The PCR amplicons
were analyzed using an ABI 3730xl analyzer and Genemapper software. Three independent experiments were performed. (A). Representative output
from the Genemapper programme. The panels from top to bottom represent input chromatin DNA, chromatin immunoprecipitated with the p50
antibody, and chromatin immunoprecipitated with the p65 antibody. (B). Chart shows mean (6 standard error of mean) of the relative peak heights
of the 5A and 6A alleles in the p50 and p65 antibody precipitates, standardized against the relative peak heights of the 5A and 6A alleles in the input
DNA, in three independent experiments. * denotes p,0.05 comparing 5A versus 6A alleles.
doi:10.1371/journal.pone.0009902.g004
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polymorphism and indicate that this effect is likely to derive from
differential effects of NFkB on the 5A and 6A alleles.
In conclusion, the findings of this study are highly relevant to
the understanding of the transcriptional regulation of MMP3,
increased expression of which has been suggested to play an
important role in atherosclerotic plaque rupture [3–5]. In
addition, they provide an insight into the functional effect of the
5A/6A polymorphism which has been associated with a number
of cardiovascular traits including risk of myocardial infarction
[14].
Materials and Methods
Chemicals
Lipopolysaccharide was obtained from Sigma. 6-Amino-4-(4-
phenoxyphenylethylamino)- quinazoline was from Merck Chem-
icals Ltd. Antibodies for p50 (ab7971), p65 (ab32536 and ab7970)
and MMP3 (ab53015) were from Abcam. ChIP assay kit was from
Upstate Biotechnology.
Immunohistochemistry
Immunohistochemical analyses were performed on 4 mm
sections of formalin-fixed and paraffin-embedded tissue blocks of
atherosclerotic plaques removed from patients undergoing carotid
endarterectomy. The study was approved by the South and West
Local Research Ethics Committee, and all participants provided
written informed consent. Tissue sections were pretreated with
Tris-EDTA pH 9.0. Immunostaining was carried out as described
previously [40]. We used rabbit polyclonal NFkB p50 (ab7971,
Abcam) and MMP3 antibodies (ab53015, Abcam), a rabbit
monoclonal NFkB p65 antibody (ab32536, Abcam), and mouse
monoclonal CD68 (clone PG-M1) and smooth muscle alpha-actin
(SMA, clone 1A4) antibodies (Dako, Glostrup, Denmark),
respectively. Secondary antibodies were goat anti-mouse IgG or
anti-rabbit IgG/alkaline phosphatase (AP) polymers (Thermo/
LabVision, Fremont, CA). The sequential AP double immuno-
staining was performed as previously described [41] with Liquid
Permanent Red (Dako) and Vector Blue used as chromogens
(Vector Labs, Burlingame, CA).
Cell culture
THP1 and RAW264 cells were purchased from the American
Type Culture Collection (ATCC) and the European Collection of
Cell Cultures (ECACC), respectively. THP1 cells were maintained
in RPMI-1640 medium (ATCC) supplemented with 10% foetal
bovine serum (Invitrogen), 2 mM L-glutamine (Invitrogen), 50 U/
ml penicillin and 50 mg/ml streptomycin (Invitrogen). RAW264
cells were maintained in DMEM medium (Sigma) supplemented
with 10% foetal bovine serum (Invitrogen), 2 mM L-glutamine
(Invitrogen), 50 U/ml penicillin and 50 mg/ml streptomycin
(Invitrogen). The cells were incubated at 37uC in a cell incubator
supplied with 5% CO2.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was carried out by using a
chromatin immunoprecipitation kit from Upstate Biotechnology
according to the manufacturer manual. Briefly, THP1 cells were
grown to density at 0.8–16106 cells per ml of culture medium.
Proteins were cross-linked to DNA by adding 37% of formalde-
hyde directly to the medium to a final concentration of 1%, and
after 10 minutes of incubation at room temperature, unreacted
formaldehyde was quenched with 0.125 M glycine for 5 minutes.
Cells were pelleted, washed 2–3 times in ice-cold phosphate
buffered saline and lysed in lysis buffer with protease inhibitors for
10 minutes on ice. The lysate was sonicated to reduce DNA length
to 200–1000 bp and then spun at 10,000 g at 4uC for 10 minutes
to remove insoluble materials. Immunoprecipitation of chromatin
was performed by incubation with 2 mg anti-p50 antibody
(ab7971, Abcam) or 2 mg anti-p65 antibody (ab7970, Abcam) at
4uC for 18 hours. Incubation with 2 mg rabbit IgG was used as a
control. Following the immunoprecipitation, PCR was carried out
to amplify the DNA sequence surrounding the MMP3 gene 5A/
6A site, followed by agarose gel electrophoresis of the PCR
products. Intensity of bands on the agarose gels were quantified
with the computer software ImageJ. The fold enrichment of DNA
precipitated with p50 antibody or p65 antibody, relative to the
IgG control, was calculated by comparing the intensity of the band
of the amplicon from the p50 or p65 antibody precipitate to the
intensity of the band of the amplicon from the IgG control. Four
independent experiments were carried out.
Analysis of chromatin immunoprecipitation products
To detect chromatin immunoprecipitates, purified DNA was
analyzed by PCR using specific MMP3 promoter primers covering
the 5A/6A polymorphic site: 59-AATTCACATCACTGC-
CACCA-39 and 59-CTCTGTGGCAATAAGATCCC-39, and
PCR products were analysed on 2% agarose gels with GelRed
staining. Intensity of bands on the agarose gels were quantified
with the computer software ImageJ.
To compare the relative amounts of the 5A and 6A alleles in the
chromatin immunoprecipitates, purified DNA obtained from
chromatin immunoprecipitation was subject to PCR with a 6-
FAM-labelled forward primer (59-AATTCACATCACTGC-
CACCA-39) and an unlabelled reverse primer (59-GATTACA-
GACATGGGTCACG-39) flanking the 5A/6A polymorphic site,
with expected amplicons of 179 bp from the 5A allele and 180 bp
from the 6A allele. The PCR reactions were carried out using
Phire Hot Start DNA polymerase to generate blunt ended PCR
products. The fluorescence labelled PCR fragments were analyzed
using an ABI 3730xl analyzer and Genemapper software. Three
Figure 5. Lipopolysaccharide increases 5A allele activity.
RAW264 cells were transfected with an MMP3 5A-firefly luciferase
reporter plasmid or an MMP3 6A-firefly luciferase reporter plasmid, and
the pRL-TK plasmid (expressing renilla luciferase) to serve as a reference
for transfection efficiency. Transfected cells were cultured for 24 hours
in the absence or presence of lipopolysaccharides. Luciferase reporter
assay was performed using a dual-luciferase reporter assay system. Data
shown are mean (6 standard error of mean) of the ratio of firefly
luciferase activity over renilla luciferase activity from four independent
experiments. Asterisk indicates p,0.05 comparing untreated 5A and
LPS treated 5A.
doi:10.1371/journal.pone.0009902.g005
Allelic Regulation of MMP3
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9902
independent experiments were performed. The relative peak
heights of the 5A and 6A alleles in the p50 and p65 antibody
precipitates were standardized against the relative peak heights of
the 5A and 6A alleles in the input DNA and compared by a t-test.
Plasmids
TheMMP3 5A and 6A pGL3 reporter constructs were produced by
cloning three copies of the 5A or 6A polymorphic site of the human
MMP3 gene: 59-ACAAGACATGGTTTTT(T)CCCCCCAT-
CAAAGA-39 into the pGL3 promoter vector (Promega), upstream
of the SV40 promoter and the luciferase gene. NFkB p50, NFkB p65
and p300 expressing plasmids have been described [42–44]. The
IKKb dominate negative plasmid has been described previously [45].
Transfection and luciferase reporter assay
The day before transfection, RAW264 cells were plated into 24-
well tissue culture dishes at a density reaching 70–80% confluence
by the following day. Cells were transfected with the MMP3 5A-
luciferase reporter plasmid or the MMP3 6A-luciferase reporter
plasmid, and the pRL-TK plasmid (Promega) to serve as a
reference for transfection efficiency. Transfected cells were
cultured for 24 hours in the absence or presence of LPS
(100 ng/ml) or 6-Amino-4-(4-phenoxyphenylethylamino)-quina-
zoline (10 mM). In some experiments, the cells were also
transfected with a p50 expression plasmid and/or a p65 expression
plasmid, or with a pcDNA3 plasmid to serve as a control, or with a
plasmid expressing a dominant negative mutant of IKKb.
Transfections were performed in duplicates with FuGENE 6
transfection reagent (Roche) using a protocol provided by the
supplier. Luciferase reporter assay was performed using a dual-
luciferase reporter assay system (Promega). Transfections and cell
treatments were performed in duplicate and individual experi-
ments were repeated at least three times.
Statistical analysis
In the chromatin immunoprecipitation assays, the PCR band
itensities of DNA precipitated with p50 antibody or p65 antibody
were compared with the IgG control by Mann-Whitney test. The
relative peak heights of the 5A and 6A alleles in the p50 and p65
antibody precipitates in the Genemaper programme outputs were
standardized against the relative peak heights of the 5A and 6A
alleles in the input DNA and compared by a t-test. In the
luciferases reporter assays, t-tests were performed to compare
differences between the 5A and 6A alleles and between different
the treated and untreated. All data are represented as the mean 6
standard error of mean (SEM).
Figure 6. NFkB has a greater upregulatory effect on the 5A allele than the 6A allele. RAW264 cells were transfected with an MMP3 5A-
firefly luciferase reporter plasmid or an MMP3 6A-firefly luciferase reporter plasmid, and the pRL-TK plasmid (expressing renilla luciferase) to serve as a
reference for transfection efficiency, together with a plasmid expressing p50 and/or a plasmid expressing p65. Luciferase reporter assay was
performed using a dual-luciferase reporter assay system. Data shown are mean (6 standard error of mean) of the ratio of firefly luciferase activity over
renilla luciferase activity from four independent experiments. In panel (A), * indicates p= 0.07 comparing 5A and 5A plus p50. In panel (B), ** indicates
p,0.01 comparing 5A and 5A plus p65. In panel (C), * denotes p,0.05 comparing 5A with 5A plus p50 and p65.
doi:10.1371/journal.pone.0009902.g006
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